All In Biotech

Drug Trial Radar · NCT05923866

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

A Phase 2, Double-blind, Placebo-controlled, Parallel-group Study Followed by an Open-label, Parallel Group Extension Part to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Potential Efficacy of Multiple Doses of ONO-2808 in Patients With Multiple System Atrophy

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

92

Actual

Start

Sep 22, 2023

Primary completion

Sep 15, 2025

Study completion Oct 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jun 28, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 30 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, double-blind, parallel-group, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of multiple doses of ONO-2808 in patients with MSA. This is the first study of ONO-2808 in patients with MSA.

Conditions

  • Multiple System Atrophy (MSA)

Interventions

  • ONO-2808Drug

    Oral administration of ONO-2808 at low, middle or high doses once daily for 24 weeks in the core part, for a total of 80 weeks including the extension part, and for up to an additional 72 weeks in the additional extension part

  • PlaceboDrug

    Oral administration of placebo once daily for 24 weeks in the core part and for a total of 32 weeks including the extension part; Transition to low-dose of ONO-2808 for remainder of the extension part until week 80 and for up to an additional 72 weeks in the additional extension part

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)Time frame: From screening up to follow-up for the core part (up to Week 28)
  2. Incidence of TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)
  3. Incidence of Study Treatment-related TEAEs by Highest SeverityTime frame: From screening up to follow-up for the core part (up to Week 28)

Locations

35 sites in 2 countries. Site status is shown where the registry gives one.

  • The Parkinson's Movement and Disorder Institute

    Fountain Valley, California

  • University of Southern California

    Los Angeles, California

  • David Geffen School of Medicine at UCLA

    Los Angeles, California

  • Stanford University School of Medicine

    Palo Alto, California

  • CenExel Rocky Mountain Clinical Research

    Englewood, Colorado

  • Yale School of Medicine - Yale Church Street Research Unit (CRSU)

    New Haven, Connecticut

  • Parkinson's Disease and Movement Disorders Center of Boca Raton

    Boca Raton, Florida

  • Norman Fixel Institute for Neurological Diseases - University of Florida

    Gainesville, Florida

  • Mayo Clinic in Florida

    Jacksonville, Florida

  • University of Miami Miller School of Medicine

    Miami, Florida

  • Emory University School of Medicine

    Atlanta, Georgia

  • University of Kansas Medical Center Research Institute

    Kansas City, Kansas

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • University of Michigan School of Medicine

    Ann Arbor, Michigan

  • Quest Research Institute

    Farmington Hills, Michigan

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • NYU Langone Health - NYU Dysautonomia Center

    New York, New York

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University

    New York, New York

  • University of Cincinnati College of Medicine

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • Ohio State University

    Columbus, Ohio

  • Penn State University - Milton S. Hershey Medical Center

    Hershey, Pennsylvania

  • The University of Pennsylvania - Pennsylvania Hospital

    Philadelphia, Pennsylvania

  • UT Southwestern Medical Center

    Dallas, Texas

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia

  • Evergreen Health

    Kirkland, Washington

  • Swedish Neuroscience Institute, Movement Disorders Clinic

    Seattle, Washington

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, Japan

  • National Hospital Organization Utano National Hospital

    Kyoto, Kyoto, Japan

  • National Hospital Organization Sendai Nishitaga Hospital

    Sendai, Miyagi, Japan

  • National Hospital Organization Osaka Toneyama Medical Center

    Toyonaka, Osaka, Japan

  • Tokyo Metropolitan Neurological Hospital

    Fuchū, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.